MiR-205 as predictive biomarker and adjuvant therapeutic tool in combination with trastuzumab

Trastuzumab is the standard treatment for HER2+ breast cancer (BC) patients, and even though it significantly improved their clinical outcome, 50% of them do not benefit from this drug and disease recurs, underlining the need of reliable predictive biomarkers and new therapeutic strategies. Striking...

Descripción completa

Detalles Bibliográficos
Autores principales: Cataldo, Alessandra, Piovan, Claudia, Plantamura, Ilaria, D’Ippolito, Elvira, Camelliti, Simone, Casalini, Patrizia, Giussani, Marta, Déas, Olivier, Cairo, Stefano, Judde, Jean-Gabriel, Tagliabue, Elda, Iorio, Marilena V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021348/
https://www.ncbi.nlm.nih.gov/pubmed/29963251
http://dx.doi.org/10.18632/oncotarget.24723

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021348/
https://www.ncbi.nlm.nih.gov/pubmed/29963251
http://dx.doi.org/10.18632/oncotarget.24723

Ejemplares similares